Skip to main content
. 2014 Jan 3;14(3):167–173. doi: 10.1007/s40256-013-0058-8

Fig. 2.

Fig. 2

Effects of ACE inhibitors and ARBs on the risks of clinical endpoints in high-risk cardiovascular patients without heart failure [15, 16]. ACE angiotensin-converting enzyme, ARBs angiotensin receptor blockers, CV cardiovascular, NS not significant